Paliperidone

Generic name: Pronounced as (pal ee per' i done)
Brand names
  • Invega®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2017

Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as paliperidone have an increased risk of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or ministroke during treatment.

Paliperidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior problems in older adults with dementia. Talk to the doctor who prescribed this medication, if you, a family member, or someone you care for has dementia and is taking paliperidone. For more information, visit the FDA website: http://www.fda.gov/Drugs

Paliperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Paliperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Paliperidone comes as an extended-release (long-acting) tablet to take by mouth. It is usually taken once a day in the morning with or without food. Take paliperidone at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take paliperidone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole with plenty of water or other liquid. Do not split, chew, or crush the tablets. Tell your doctor if you cannot swallow tablets. Your doctor will probably prescribe another medication to treat your condition.

Talk to your doctor about how you are feeling during your treatment. If your symptoms are still bothersome, your doctor may gradually increase your dose, not more often than once every 5 days.

Paliperidone controls the symptoms of schizophrenia but does not cure the condition. Continue to take paliperidone even if you feel well. Do not stop taking paliperidone without talking to your doctor.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking paliperidone,

  • tell your doctor and pharmacist if you are allergic to paliperidone, risperidone (Risperdal), or any other medications.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants; certain antibiotics such as erythromycin (E.E.S., E-Mycin, Erythrocin), gatifloxacin (Tequin) (not available in the United States), moxifloxacin (Avelox), and sparfloxacin (Zagam); certain antipsychotics such as chlopromazine (Sonazine, Thorazine), pimozide (Orap), risperidone (Risperdal) and thioridazine; cisapride (Propulsid); levodopa (in Sinemet, in Stalevo); medications for anxiety, high blood pressure, or seizures; medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), dofetilide (Tikosyn); procainamide (Procanbid, Pronestyl), quinidine (Quinidex), and sotalol (Betapace, Betapace AF); sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had a prolonged QT interval (a rare heart problem that may cause fainting or irregular heartbeat); slow or irregular heartbeat; a heart attack; low levels of potassium or magnesium in your blood; seizures; trouble keeping your balance; a stroke; a head injury; a brain tumor; Parkinson's disease (a disorder of the nervous system that causes difficulties with movement, muscle control, and balance); diabetes; breast cancer; surgery involving the intestines; any condition that causes blockage or narrowing of the esophagus (tube that connects the mouth and stomach), stomach, or intestines such as cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction), and inflammatory bowel disease (IBD; a group of conditions that cause swelling of the lining of the intestines); and kidney, heart, or liver disease. Also tell your doctor if you drink or have ever drunk large amounts of alcohol and if you use or have ever used street drugs or have overused prescription medications. Tell your doctor if you have ever had to stop taking a medication for mental illness because of severe side effects.

  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking paliperidone, call your doctor. Paliperidone may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking paliperidone.

  • you should know that paliperidone may make you drowsy and may cause difficulty with thinking and movement. Do not drive a car or operate machinery until you know how this medication affects you.

  • you should know that alcohol may add to the drowsiness caused by paliperidone. Do not drink alcoholic beverages while you are taking this medication.

  • you should know that you may experience hyperglycemia (increases in your blood sugar) while you are taking this medication, even if you do not already have diabetes. If you have schizophrenia, you may be more likely to develop diabetes than people who do not have schizophrenia, and taking paliperidone or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are taking paliperidone: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar can cause more serious symptoms, such as dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, or decreased consciousness, and may become life-threatening if it is not treated at an early stage.

  • you should know that paliperidone may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to exercise or be exposed to extreme heat.

  • you should know that paliperidone may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking paliperidone or when your dose is increased. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Paliperidone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • dizziness, feeling unsteady, or having trouble keeping your balance

    • extreme tiredness

    • weakness

    • headache

    • dry mouth

    • increased saliva

    • weight gain

    • stomach pain

  • Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

    • fever

    • muscle pain or stiffness

    • falling

    • confusion

    • fast, pounding, or irregular heartbeat

    • sweating

    • unusual movements of your face or body that you cannot control

    • slow or stiff movements

    • restlessness

    • painful erection of the penis that lasts for hours

  • Paliperidone may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • unusual movements of your face or body that you cannot control

  • slow or stiff movements

  • restlessness

  • unsteadiness

  • drowsiness

  • fast heartbeat

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

You may notice something that looks like a tablet in your stool. This is just the empty tablet shell and does not mean that you did not get your complete dose of medication.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone.
Repaglinide Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Paliperidone.
Delavirdine Delavirdine The metabolism of Paliperidone can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Paliperidone can be decreased when combined with Nevirapine.
Atorvastatin Atorvastatin The metabolism of Paliperidone can be decreased when combined with Atorvastatin.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Paliperidone.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Paliperidone.
Candesartan Candesartan Paliperidone may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Paliperidone.
Clopidogrel Clopidogrel The metabolism of Paliperidone can be decreased when combined with Clopidogrel.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Paliperidone.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fenofibrate Fenofibrate Fenofibrate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Paliperidone.
Magnesium Hydroxide Magnesium Hydroxide Paliperidone may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Paliperidone.
Miglitol Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.
Mycophenolate Mycophenolate Mycophenolic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Paregoric Paregoric The serum concentration of Morphine can be increased when it is combined with Paliperidone.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Paliperidone.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.
Potassium Potassium Potassium may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Prednisone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ranitidine Ranitidine The metabolism of Paliperidone can be decreased when combined with Ranitidine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.
Tacrolimus Tacrolimus The metabolism of Paliperidone can be decreased when combined with Tacrolimus.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Paliperidone.
Triamcinolone Triamcinolone The metabolism of Paliperidone can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Paliperidone.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Paliperidone.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Paliperidone.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Paliperidone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Paliperidone.
Morphine Injection Morphine Injection The serum concentration of Morphine can be increased when it is combined with Paliperidone.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Paliperidone may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Paliperidone.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Paliperidone.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Paliperidone.
Torsemide Torsemide Torasemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine Olanzapine Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Paliperidone.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Paliperidone.
Entacapone Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Paliperidone.
Eprosartan Eprosartan Paliperidone may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Paliperidone.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paliperidone.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Telmisartan Telmisartan Paliperidone may decrease the antihypertensive activities of Telmisartan.
Temozolomide Temozolomide Temozolomide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.
Anakinra Anakinra The metabolism of Paliperidone can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Paliperidone.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Paliperidone.
Trimipramine Trimipramine Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Etanercept Injection Etanercept Injection The metabolism of Paliperidone can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Paliperidone can be increased when combined with Modafinil.
Perindopril Perindopril Perindopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sirolimus Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Paliperidone.
Dutasteride Dutasteride The metabolism of Paliperidone can be decreased when combined with Dutasteride.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Epinephrine can be decreased when used in combination with Paliperidone.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Paliperidone.
Olmesartan Olmesartan Paliperidone may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Paliperidone.
Adalimumab Injection Adalimumab Injection The metabolism of Paliperidone can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Paliperidone.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Paliperidone.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Paliperidone.
Rosuvastatin Rosuvastatin The metabolism of Paliperidone can be decreased when combined with Rosuvastatin.
Vardenafil Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Paliperidone.
Alfuzosin Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Aprepitant Aprepitant The metabolism of Paliperidone can be decreased when combined with Aprepitant.
Emtricitabine Emtricitabine Emtricitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Memantine Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Paliperidone.
Tegaserod Tegaserod The metabolism of Tegaserod can be decreased when combined with Paliperidone.
Tadalafil Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Tadalafil is combined with Paliperidone.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Paliperidone.
Progesterone Progesterone The metabolism of Paliperidone can be decreased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Paliperidone.
Infliximab Injection Infliximab Injection The metabolism of Paliperidone can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Paliperidone.
Rifaximin Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Paliperidone.
Duloxetine Duloxetine The metabolism of Paliperidone can be decreased when combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Paliperidone can be decreased when combined with Norethisterone.
Tinidazole Tinidazole Tinidazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trospium Trospium Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan Paliperidone may decrease the antihypertensive activities of Bosentan.
Cefditoren Cefditoren Cefdinir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Paliperidone can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Erlotinib Erlotinib The metabolism of Paliperidone can be decreased when combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Paliperidone is combined with Eszopiclone.
Ganciclovir Ganciclovir Ganciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Paliperidone.
Ribavirin Ribavirin Ribavirin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Paliperidone.
Valganciclovir Valganciclovir Paliperidone may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Paliperidone.
Adefovir Adefovir Adefovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Paliperidone can be decreased when combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Exenatide Injection Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Paliperidone.
Darifenacin Darifenacin The metabolism of Darifenacin can be decreased when combined with Paliperidone.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.
Pregabalin Pregabalin The therapeutic efficacy of Paliperidone can be increased when used in combination with Pregabalin.
Phenylephrine Phenylephrine The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Paliperidone.
Tipranavir Tipranavir The serum concentration of Tipranavir can be decreased when it is combined with Paliperidone.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Paliperidone.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Paliperidone.
Ranolazine Ranolazine The serum concentration of Paliperidone can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Paliperidone can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Paliperidone is combined with Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Paliperidone.
Sitagliptin Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Paliperidone.
Varenicline Varenicline Paliperidone may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib Gefitinib The metabolism of Paliperidone can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Paliperidone.
Bortezomib Bortezomib The serum concentration of Paliperidone can be increased when it is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection Clofarabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Paliperidone.
Lubiprostone Lubiprostone Lubiprostone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Paliperidone.
Primaquine Primaquine The metabolism of Paliperidone can be decreased when combined with Primaquine.
Aliskiren Aliskiren Paliperidone may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Paliperidone may increase the neurotoxic activities of Bismuth subsalicylate.
Pemetrexed Injection Pemetrexed Injection Paliperidone may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Paliperidone.
Lisdexamfetamine Lisdexamfetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Paliperidone.
Sorafenib Sorafenib The metabolism of Paliperidone can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The metabolism of Paliperidone can be decreased when combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Paliperidone.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Paliperidone.
Pegaptanib Injection Pegaptanib Injection Paliperidone may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Paliperidone.
Mexiletine Mexiletine The metabolism of Paliperidone can be decreased when combined with Mexiletine.
Armodafinil Armodafinil The metabolism of Paliperidone can be increased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Azacitidine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Temsirolimus Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Paliperidone.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Paliperidone.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Paliperidone.
Budesonide Budesonide The metabolism of Paliperidone can be increased when combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Paliperidone can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Paliperidone.
Doripenem Injection Doripenem Injection Paliperidone may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine Etravirine The serum concentration of Paliperidone can be decreased when it is combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Paliperidone.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Paliperidone is combined with Desvenlafaxine.
Cevimeline Cevimeline Cevimeline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nebivolol Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Paliperidone.
Tretinoin Tretinoin The metabolism of Paliperidone can be decreased when combined with Tretinoin.
Bendamustine Injection Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Paliperidone.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Paliperidone.
Certolizumab Injection Certolizumab Injection The metabolism of Paliperidone can be increased when combined with Certolizumab pegol.
Irinotecan Injection Irinotecan Injection The metabolism of Paliperidone can be decreased when combined with Irinotecan.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Praziquantel Praziquantel The metabolism of Paliperidone can be decreased when combined with Praziquantel.
Methylnaltrexone Injection Methylnaltrexone Injection Paliperidone may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.
Silodosin Silodosin The serum concentration of Silodosin can be increased when it is combined with Paliperidone.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.
Naltrexone Injection Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paliperidone.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Milnacipran.
Plerixafor Injection Plerixafor Injection Paliperidone may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine Fesoterodine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Paliperidone.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Paliperidone.
Iloperidone Iloperidone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.
Prasugrel Prasugrel Paliperidone may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Paliperidone is combined with Lacosamide.
Everolimus Everolimus The serum concentration of Everolimus can be increased when it is combined with Paliperidone.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Paliperidone.
Dronedarone Dronedarone Paliperidone may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
Pralatrexate Injection Pralatrexate Injection Paliperidone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Paliperidone.
Saxagliptin Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Paliperidone.
Romidepsin Injection Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Paliperidone.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Paliperidone.
Golimumab Injection Golimumab Injection The metabolism of Paliperidone can be increased when combined with Golimumab.
Pazopanib Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Paliperidone.
Asenapine Asenapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paliperidone.
Levonorgestrel Levonorgestrel The metabolism of Paliperidone can be decreased when combined with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.
Liraglutide Injection Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Paliperidone can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine Paliperidone may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Paliperidone.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Paliperidone.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Lurasidone Lurasidone Paliperidone may increase the hypotensive activities of Lurasidone.
Acetaminophen Injection Acetaminophen Injection Acetaminophen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vilazodone Vilazodone The metabolism of Vilazodone can be decreased when combined with Paliperidone.
Ipilimumab Injection Ipilimumab Injection Paliperidone may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Paliperidone.
Roflumilast Roflumilast Paliperidone may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Paliperidone.
Rilpivirine Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Paliperidone.
Telaprevir Telaprevir The serum concentration of Glecaprevir can be increased when it is combined with Paliperidone.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Paliperidone can be decreased when combined with Cyclophosphamide.
Abiraterone Abiraterone The metabolism of Paliperidone can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Paliperidone.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Paliperidone.
Ticagrelor Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Paliperidone.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Paliperidone.
Ruxolitinib Ruxolitinib Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Vandetanib.
Clobazam Clobazam The metabolism of Paliperidone can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paliperidone.
Ivacaftor Ivacaftor The serum concentration of Paliperidone can be increased when it is combined with Ivacaftor.
Deferiprone Deferiprone Paliperidone may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The serum concentration of Axitinib can be increased when it is combined with Paliperidone.
Crizotinib Crizotinib The serum concentration of Paliperidone can be increased when it is combined with Crizotinib.
Cabergoline Cabergoline The serum concentration of Paliperidone can be increased when it is combined with Cabergoline.
Naloxone Injection Naloxone Injection Naloxone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Paliperidone.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Paliperidone.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Carfilzomib can be increased when it is combined with Paliperidone.
Enzalutamide Enzalutamide The serum concentration of Paliperidone can be increased when it is combined with Enzalutamide.
Mirabegron Mirabegron The metabolism of Paliperidone can be decreased when combined with Mirabegron.
Regorafenib Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Paliperidone.
Bosutinib Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Paliperidone.
Lorcaserin Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Paliperidone.
Teduglutide Injection Teduglutide Injection Paliperidone may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Paliperidone.
Alogliptin Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Paliperidone.
Pomalidomide Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Paliperidone.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Paliperidone.
Apixaban Apixaban The serum concentration of Apixaban can be increased when it is combined with Paliperidone.
Canagliflozin Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Paliperidone.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The serum concentration of Paliperidone can be increased when it is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Paliperidone can be decreased when combined with Ospemifene.
Trametinib Trametinib Paliperidone may decrease the excretion rate of Trametinib which could result in a higher serum level.
Dolutegravir Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Paliperidone.
Afatinib Afatinib The serum concentration of Afatinib can be increased when it is combined with Paliperidone.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Paliperidone.
Lomitapide Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Paliperidone.
Avanafil Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Paliperidone.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Simeprevir Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Paliperidone.
Sofosbuvir Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Paliperidone.
Dapagliflozin Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Paliperidone.
Apremilast Apremilast The metabolism of Paliperidone can be increased when combined with Apremilast.
Droxidopa Droxidopa The therapeutic efficacy of Droxidopa can be decreased when used in combination with Paliperidone.
Ceritinib Ceritinib The serum concentration of Paliperidone can be increased when it is combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Paliperidone can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Paliperidone.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Paliperidone is combined with Eslicarbazepine.
Belinostat Injection Belinostat Injection The serum concentration of Belinostat can be increased when it is combined with Paliperidone.
Idelalisib Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Paliperidone.
Testosterone Injection Testosterone Injection Testosterone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oritavancin Injection Oritavancin Injection The metabolism of Paliperidone can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.
Vorapaxar Vorapaxar The serum concentration of Paliperidone can be increased when it is combined with Vorapaxar.
Hydrocodone Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Suvorexant Suvorexant Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.
Edoxaban Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Paliperidone.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Paliperidone.
Methamphetamine Methamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon.
Riociguat Riociguat Paliperidone may decrease the antihypertensive activities of Riociguat.
Nintedanib Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Paliperidone.
Secukinumab Injection Secukinumab Injection The metabolism of Paliperidone can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.
Palbociclib Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Paliperidone.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Paliperidone.
Naloxegol Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Paliperidone.
Panobinostat Panobinostat The metabolism of Paliperidone can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Paliperidone can be increased when it is combined with Isavuconazonium.
Macitentan Macitentan Paliperidone may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The serum concentration of Paliperidone can be increased when it is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Paliperidone can be decreased when combined with Rolapitant.
Daclatasvir Daclatasvir The serum concentration of Paliperidone can be increased when it is combined with Daclatasvir.
Brexpiprazole Brexpiprazole Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Paliperidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Paliperidone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline Eluxadoline The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Paliperidone.
Cobimetinib Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Paliperidone.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Paliperidone.
Osimertinib Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Paliperidone.
Ixazomib Ixazomib Paliperidone may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Paliperidone may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The metabolism of Paliperidone can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brivaracetam.
Venetoclax Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Paliperidone.
Cobicistat Cobicistat The metabolism of Paliperidone can be decreased when combined with Cobicistat.
Midodrine Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Paliperidone.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Paliperidone.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Paliperidone is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Paliperidone.
Furosemide Injection Furosemide Injection Furosemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Paliperidone.
Lixisenatide Injection Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Paliperidone.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.
Deutetrabenazine Deutetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Deutetrabenazine.
Valbenazine Valbenazine Paliperidone may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Deflazacort Deflazacort The metabolism of Paliperidone can be increased when combined with Deflazacort.
Safinamide Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Paliperidone.
Naldemedine Naldemedine Paliperidone may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Paliperidone can be decreased when combined with Midostaurin.
Neratinib Neratinib The serum concentration of Paliperidone can be increased when it is combined with Neratinib.
Enasidenib Enasidenib The metabolism of Paliperidone can be decreased when combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paliperidone.
Benznidazole Benznidazole Paliperidone may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Paliperidone.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Paliperidone.
Abemaciclib Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Paliperidone.
Betrixaban Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Paliperidone.
Acalabrutinib Acalabrutinib The metabolism of Paliperidone can be decreased when combined with Acalabrutinib.
Letermovir Letermovir The metabolism of Paliperidone can be decreased when combined with Letermovir.
Semaglutide Injection Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Paliperidone.
Tetrabenazine Tetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Paliperidone.
Buprenorphine Injection Buprenorphine Injection Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Paliperidone can be decreased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Paliperidone.
Avatrombopag Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Paliperidone.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Paliperidone.
Lofexidine Lofexidine The therapeutic efficacy of Paliperidone can be increased when used in combination with Lofexidine.
Plazomicin Injection Plazomicin Injection Paliperidone may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Encorafenib.
Binimetinib Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Paliperidone.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Paliperidone.
Lusutrombopag Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Paliperidone.
Elagolix Elagolix The serum concentration of Elagolix can be increased when it is combined with Paliperidone.
Doravirine Doravirine The metabolism of Doravirine can be decreased when combined with Paliperidone.
Tafenoquine Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Paliperidone.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Paliperidone.
Dacomitinib Dacomitinib The serum concentration of Paliperidone can be increased when it is combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Paliperidone.
Omadacycline Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Paliperidone.
Sarecycline Sarecycline The serum concentration of Paliperidone can be increased when it is combined with Sarecycline.
Stiripentol Stiripentol The metabolism of Paliperidone can be decreased when combined with Stiripentol.
Talazoparib Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Paliperidone.
Gilteritinib Gilteritinib The therapeutic efficacy of Paliperidone can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Paliperidone.
Larotrectinib Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Paliperidone.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Paliperidone.
Rifamycin Rifamycin The serum concentration of Rifamycin can be increased when it is combined with Paliperidone.
Prucalopride Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Paliperidone.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Paliperidone can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of hypertension can be increased when Paliperidone is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Erdafitinib Erdafitinib The serum concentration of Paliperidone can be increased when it is combined with Erdafitinib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Paliperidone.
Darolutamide Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Paliperidone.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Paliperidone.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib.
Istradefylline Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Paliperidone.
Pitolisant Pitolisant The serum concentration of Paliperidone can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Paliperidone.
Lefamulin Lefamulin Paliperidone may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Paliperidone.
Fosphenytoin Injection Fosphenytoin Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Paliperidone is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Paliperidone.
Tazemetostat Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Paliperidone.
Cenobamate Cenobamate The serum concentration of Paliperidone can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Paliperidone.
Rimegepant Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Paliperidone.
Tucatinib Tucatinib Paliperidone may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Remdesivir Injection Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Paliperidone.
Ripretinib Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Paliperidone.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Paliperidone is combined with Selpercatinib.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Paliperidone is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Paliperidone.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Paliperidone.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone.
Pralsetinib Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Paliperidone.
Opicapone Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Paliperidone.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Paliperidone can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Paliperidone is combined with Naxitamab.
Relugolix Relugolix The serum concentration of Relugolix can be increased when it is combined with Paliperidone.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Viloxazine.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Theophylline Theophylline The metabolism of Paliperidone can be decreased when combined with Theophylline.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Paliperidone.
Isotretinoin Isotretinoin Isotretinoin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Hydroxyurea Hydroxyurea The metabolism of Paliperidone can be decreased when combined with Hydroxyurea.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Phenobarbital Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Paliperidone.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Paliperidone.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Paliperidone.
Diethylpropion Diethylpropion The therapeutic efficacy of Paliperidone can be decreased when used in combination with Diethylpropion.
Chlorpromazine Chlorpromazine Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Paliperidone.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.
Phenoxybenzamine Phenoxybenzamine Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Carmustine Carmustine Carmustine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Paliperidone.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.
Bromocriptine Bromocriptine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Metaproterenol Metaproterenol The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Paliperidone.
Tranylcypromine Tranylcypromine The metabolism of Paliperidone can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.
Tetracycline Tetracycline Tetracycline may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Paliperidone.
Thioridazine Thioridazine Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Trifluoperazine Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dapsone Dapsone The metabolism of Paliperidone can be decreased when combined with Dapsone.
Sulfadiazine Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Paliperidone.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.
Oxybutynin Oxybutynin The metabolism of Paliperidone can be decreased when combined with Oxybutynin.
Benztropine Benztropine The risk or severity of adverse effects can be increased when Paliperidone is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Paliperidone.
Orphenadrine Orphenadrine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.
Azathioprine Azathioprine Azathioprine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.
Phentermine Phentermine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Phentermine.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
Amoxapine Amoxapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Sulfasalazine Sulfasalazine Sulfasalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Hydrocortisone Hydrocortisone The metabolism of Paliperidone can be decreased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Paliperidone.
Dactinomycin Dactinomycin The serum concentration of Paliperidone can be increased when it is combined with Dactinomycin.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Paliperidone can be decreased when combined with Carbamazepine.
Molindone Molindone The risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.
Methyldopa Methyldopa The therapeutic efficacy of Paliperidone can be decreased when used in combination with Methyldopa.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Paliperidone.
Prazosin Prazosin Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Hydralazine Hydralazine Paliperidone may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine The metabolism of Paliperidone can be decreased when combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Warfarin Warfarin Paliperidone may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Paliperidone.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Paliperidone.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Paliperidone.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Daunorubicin Daunorubicin The metabolism of Paliperidone can be increased when combined with Daunorubicin.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Digoxin Digoxin Paliperidone may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.
Chloroquine Chloroquine The metabolism of Paliperidone can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Paliperidone can be decreased when combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Paliperidone.
Triamterene Triamterene Triamterene may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Chlorothiazide Chlorothiazide Chlorothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Chlorthalidone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection Clindamycin Injection The metabolism of Paliperidone can be decreased when combined with Clindamycin.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.
Desipramine Desipramine The metabolism of Paliperidone can be decreased when combined with Desipramine.
Amitriptyline Amitriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline.
Imipramine Imipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Probenecid Probenecid Probenecid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Quinidine Quinidine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Paliperidone.
Isoniazid Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Paliperidone.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Rifampin Rifampin The serum concentration of Paliperidone can be decreased when it is combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone.
Valproic Acid Valproic Acid The serum concentration of Paliperidone can be increased when it is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Paliperidone can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.
Levothyroxine Levothyroxine The serum concentration of Paliperidone can be decreased when it is combined with Levothyroxine.
Liothyronine Liothyronine Liothyronine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Methimazole Methimazole The metabolism of Paliperidone can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Paliperidone is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Paliperidone can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Paliperidone.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Paliperidone.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Paliperidone.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Paliperidone.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Paliperidone.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Paliperidone.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Paliperidone.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Paliperidone.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paliperidone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Paliperidone.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paliperidone.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Paliperidone.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Paliperidone.
Minoxidil Minoxidil Paliperidone may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Pseudoephedrine.
Nortriptyline Nortriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Phytonadione Phytonadione Phylloquinone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nadolol Nadolol Nadolol may increase the orthostatic hypotensive activities of Paliperidone.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Paliperidone.
Clomiphene Clomiphene The serum concentration of Clomifene can be increased when it is combined with Paliperidone.
Flavoxate Flavoxate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Paliperidone.
Colchicine Colchicine The serum concentration of Colchicine can be increased when it is combined with Paliperidone.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Dacarbazine Dacarbazine Dacarbazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Paliperidone.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ketoconazole Ketoconazole The metabolism of Paliperidone can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Paliperidone is combined with Pyrantel.
Vincristine Injection Vincristine Injection The excretion of Vincristine can be decreased when combined with Paliperidone.
Captopril Captopril Paliperidone may decrease the antihypertensive activities of Captopril.
Dipyridamole Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Paliperidone.
Isoxsuprine Isoxsuprine The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Paliperidone.
Vinblastine Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Paliperidone.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Metoprolol Metoprolol The metabolism of Metoprolol can be decreased when combined with Paliperidone.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Paliperidone.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Paliperidone is combined with Thiothixene.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.
Dicyclomine Dicyclomine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Paliperidone.
Propantheline Propantheline Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim Trimethoprim may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Paliperidone.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Paliperidone.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Paliperidone.
Verapamil Verapamil Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Atenolol Atenolol Atenolol may increase the orthostatic hypotensive activities of Paliperidone.
Pindolol Pindolol Pindolol may increase the orthostatic hypotensive activities of Paliperidone.
Cisplatin Injection Cisplatin Injection Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Bumetanide Bumetanide Bumetanide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
Etoposide Etoposide The serum concentration of Paliperidone can be increased when it is combined with Etoposide.
Glyburide Glyburide The therapeutic efficacy of Paliperidone can be decreased when used in combination with Glyburide.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Paliperidone.
Amoxicillin Amoxicillin Amoxicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxacillin Injection Oxacillin Injection Oxacillin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pentoxifylline Pentoxifylline The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Paliperidone.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Paliperidone.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Labetalol Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Auranofin Auranofin Auranofin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone.
Gemfibrozil Gemfibrozil Gemfibrozil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Guanabenz Guanabenz The therapeutic efficacy of Guanabenz can be decreased when used in combination with Paliperidone.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pimozide Pimozide The metabolism of Paliperidone can be decreased when combined with Pimozide.
Enalapril Enalapril Paliperidone may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Paliperidone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Paliperidone.
Lovastatin Lovastatin The metabolism of Paliperidone can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Paliperidone.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Fluoxetine Fluoxetine The serum concentration of Paliperidone can be increased when it is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Paliperidone.
Clozapine Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.
Idarubicin Idarubicin The metabolism of Paliperidone can be decreased when combined with Idarubicin.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Paliperidone.
Didanosine Didanosine Didanosine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Paliperidone.
Benazepril Benazepril Paliperidone may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac Etodolac may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Felodipine Felodipine The metabolism of Felodipine can be decreased when combined with Paliperidone.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Pravastatin Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Paliperidone.
Quinapril Quinapril Paliperidone may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Paliperidone may decrease the antihypertensive activities of Ramipril.
Simvastatin Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Paliperidone.
Amlodipine Amlodipine The risk or severity of hypotension can be increased when Paliperidone is combined with Amlodipine.
Teniposide Injection Teniposide Injection The metabolism of Paliperidone can be decreased when combined with Teniposide.
Itraconazole Itraconazole The metabolism of Paliperidone can be decreased when combined with Itraconazole.
Lisinopril Lisinopril Lisinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Paliperidone.
Bisoprolol Bisoprolol The serum concentration of Paliperidone can be increased when it is combined with Bisoprolol.
Zolpidem Zolpidem Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Terazosin Terazosin Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Paliperidone.
Omeprazole Omeprazole The metabolism of Paliperidone can be decreased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Paliperidone.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.
Fluvastatin Fluvastatin The metabolism of Paliperidone can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The metabolism of Paliperidone can be decreased when combined with Venlafaxine.
Stavudine Stavudine Stavudine may increase the neurotoxic activities of Paliperidone.
Fluvoxamine Fluvoxamine The metabolism of Paliperidone can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.
Lamotrigine Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Paliperidone.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Paliperidone.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Paliperidone can be decreased when combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Paliperidone.
Lansoprazole Lansoprazole The metabolism of Paliperidone can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Paliperidone can be decreased when combined with Ifosfamide.
Nicardipine Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bupropion Bupropion The metabolism of Paliperidone can be decreased when combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Paliperidone can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The metabolism of Paliperidone can be decreased when combined with Saquinavir.
Metformin Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.
Nisoldipine Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Paliperidone.
Lamivudine Lamivudine Lamivudine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Paliperidone.
Acarbose Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone.
Glimepiride Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Paliperidone can be increased when it is combined with Gemcitabine.
Indinavir Indinavir The metabolism of Paliperidone can be decreased when combined with Indinavir.
Ritonavir Ritonavir The serum concentration of Paliperidone can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Paliperidone can be decreased when combined with Docetaxel.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Clomipramine Clomipramine The metabolism of Paliperidone can be decreased when combined with Clomipramine.
Fosfomycin Fosfomycin Fosfomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Mirtazapine Mirtazapine Paliperidone may increase the serotonergic activities of Mirtazapine.
Trandolapril Trandolapril Paliperidone may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Paliperidone.
Valsartan Valsartan Paliperidone may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Paliperidone.
Pramipexole Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Paliperidone.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Paliperidone.
Nelfinavir Nelfinavir The metabolism of Paliperidone can be decreased when combined with Nelfinavir.
Fexofenadine Fexofenadine The serum concentration of Paliperidone can be increased when it is combined with Fexofenadine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Paliperidone.
Carvedilol Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Nilutamide Nilutamide Nilutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Flutamide Flutamide Flutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.
Bicalutamide Bicalutamide The metabolism of Paliperidone can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Paliperidone.
Propafenone Propafenone The metabolism of Paliperidone can be decreased when combined with Propafenone.
Irbesartan Irbesartan Paliperidone may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Ropinirole Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Paliperidone.
Finasteride Finasteride The metabolism of Paliperidone can be decreased when combined with Finasteride.
Quetiapine Quetiapine Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Paliperidone.
Paroxetine Paroxetine The metabolism of Paliperidone can be decreased when combined with Paroxetine.
Tolcapone Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Paliperidone.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone.
Capecitabine Capecitabine Capecitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Paliperidone.
Abacavir Abacavir Abacavir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Sildenafil Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Paliperidone.
Pioglitazone Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.
Celecoxib Celecoxib The metabolism of Paliperidone can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Paliperidone.
Thalidomide Thalidomide Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Nateglinide Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Paliperidone.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Paliperidone.
Rabeprazole Rabeprazole Rabeprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Terbinafine Terbinafine The metabolism of Paliperidone can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists